Premium
Combination antiplatelet/antithrombotic regimens after stenting: Are we forcing too much in this decision?
Author(s) -
Nicolas Johny,
Dangas George
Publication year - 2021
Publication title -
catheterization and cardiovascular interventions
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.988
H-Index - 116
eISSN - 1522-726X
pISSN - 1522-1946
DOI - 10.1002/ccd.29574
Subject(s) - antithrombotic , medicine , regimen , intensive care medicine , randomized controlled trial , thrombosis , clinical trial , platelet aggregation inhibitor , cardiology , aspirin
Key Points Patient‐centered care entails balancing the risks and benefits of each antithrombotic therapy regimen. When assessing the risk–benefit tradeoffs of each antithrombotic therapy, all outcomes must be taken into account rather than focusing on a single outcome such as stent thrombosis. Additional randomized clinical trials are needed to establish the optimal antithrombotic therapy regimen in all patients, especially in those at high risk for bleeding and ischemic events.